Article by Merle Giles, September 19, 2017 A breath of fresh air came from Graham Anthony who spoke about the pursuit of sustainable healthcare through personalized medicine. The Biovista website calls it ‘drug repositioning’ when HPC drives the ability to more effectively and quickly combine patient and general biomedical data to transform medicine. The key … Read More
Presentation- Pursuit of Sustainable Healthcare through Personalized Medicine with HPC View the presentation by Biovista’s Graham Anthony at the HPC User Forum, Milwaukee 2017.
Article By Michael Fitzhug, Staff Writer BioWorld, Monday, August 14, 2017 Drug repositioning specialist Biovista Inc. has tapped Hewlett Packard Enterprise Co. (HPE) to add greater computing power to Project Prodigy, a personalized medicine platform that leverages artificial intelligence (AI) to help doctors identify novel drugs for hard-to-treat patients. HPE, a spin-off of HP Inc. … Read More
Biovista and Hewlett Packard Enterprise to collaborate on next generation AI and Big Data Analytics to advance real-world personalized medicine at community hospital settings. CHARLOTTESVILLE, Va., Aug. 10, 2017 /PRNewswire/ — Biovista announced today that it is collaborating with HPE to advance Biovista’s Project Prodigy Big Data AI healthcare platform applied in the personalized medicine … Read More
Vizit now indexes biomarkers! Biomarkers are widely employed as biochemical indicators of health and disease states and processes. Their usage spans a wide range of applications including disease prevention, monitoring and assessing the progress of a therapeutic regimen and the appearance of adverse drug reactions and drug interactions. In order to monitor physiological and disease … Read More